New endpoints for early-stage cancer are gaining regulatory traction
Using the standard regulatory endpoints of overall survival (OS) and progression-free survival (PFS) may not be feasible in some early-stage cancer trials due to the time it would take to reach the number of patient deaths and disease progression events to demonstrate efficacy. Novel endpoints that can offer quicker insights into the short- or long-term clinical benefits of new cancer drugs are needed, especially for early-stage cancer and immediately before (neoadjuvant) and after (adjuvant) primary treatment. This article covers three promising new endpoints.
Related Insights
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Podcast
Driving change in Cell & Gene Therapies: Key learnings from the SITC Virtual Summit
Sep 19, 2022
Blog
Leveraging the draft FDA Guidance on PBPK for your drug development program
Feb 24, 2021
Related Insights
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Podcast
Driving change in Cell & Gene Therapies: Key learnings from the SITC Virtual Summit
Sep 19, 2022
Blog
Leveraging the draft FDA Guidance on PBPK for your drug development program
Feb 24, 2021